Catalog No.
DHF19205
Expression system
Mammalian Cells
Species reactivity
Human
Host species
Human
Isotype
IgG
Target
Claudin-6, CLDN6, Skullin
Concentration
1 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Accession
P56747
Applications
Research Grade Biosimilar
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Alternative Names
DS-9606a, DS 9606a, DS9606a
Clone ID
DS-9606a
Novel therapeutics in refractory germ cell tumors., PMID:40065678
A mini-overview of antibody-drug conjugates in platinum-resistant ovarian cancer: A preclinical and clinical perspective., PMID:39922351
177Lu-Labeled Anticlaudin 6 Monoclonal Antibody for Targeted Therapy in Esophageal Cancer., PMID:39915118
Antibody-drug conjugates as targeted therapy for treating gynecologic cancers: update 2025., PMID:39480912
SAIL66, a next generation CLDN6-targeting T-cell engager, demonstrates potent antitumor efficacy through dual binding to CD3/CD137., PMID:39401967
Claudin 1, 4, 6 and 18 isoform 2 as targets for the treatment of cancer (Review)., PMID:39301632
Preclinical efficacy and pharmacokinetics of an RNA-encoded T cell-engaging bispecific antibody targeting human claudin 6., PMID:38776391
Tight Junction Proteins as Therapeutic Targets to Treat Liver Fibrosis and Hepatocellular Carcinoma., PMID:38648796
Antibody-mediated targeting of Claudins in cancer., PMID:38371623
Systematic characterization of antibody-drug conjugate targets in central nervous system tumors., PMID:37870091
The tight junction protein claudin 6 is a potential target for patient-individualized treatment in esophageal and gastric adenocarcinoma and is associated with poor prognosis., PMID:37592303
[Advances of Claudin6-targeting drugs in cancer therapy]., PMID:37154307
Targeting CLDN6 in germ cell tumors by an antibody-drug-conjugate and studying therapy resistance of yolk-sac tumors to identify and screen specific therapeutic options., PMID:36991316
Preclinical Efficacy of the Antibody-Drug Conjugate CLDN6-23-ADC for the Treatment of CLDN6-Positive Solid Tumors., PMID:36884217
Antibody specificity against highly conserved membrane protein Claudin 6 driven by single atomic contact point., PMID:36505931
A phase II study assessing the safety and efficacy of ASP1650 in male patients with relapsed refractory germ cell tumors., PMID:35759134
Claudins and Gastric Cancer: An Overview., PMID:35053454
Identification of Claudin-6 as a Molecular Biomarker in Pan-Cancer Through Multiple Omics Integrative Analysis., PMID:34409042
Targeting tumor lineage plasticity in hepatocellular carcinoma using an anti-CLDN6 antibody-drug conjugate., PMID:33536280
Prognostic Significance of Aberrant Claudin-6 Expression in Endometrial Cancer., PMID:32987797
New Anti-Cancer Strategies in Testicular Germ Cell Tumors., PMID:30636617
Antigen-specific oncolytic MV-based tumor vaccines through presentation of selected tumor-associated antigens on infected cells or virus-like particles., PMID:29203786
Displaying Tetra-Membrane Spanning Claudins on Enveloped Virus-Like Particles for Cancer Immunotherapy., PMID:29131519
Humanisation of a claudin-1-specific monoclonal antibody for clinical prevention and cure of HCV infection without escape., PMID:28360099
Identification of Novel Functions for Hepatitis C Virus Envelope Glycoprotein E1 in Virus Entry and Assembly., PMID:28179528
Claudin-6 enhances cell invasiveness through claudin-1 in AGS human adenocarcinoma gastric cancer cells., PMID:27914788
Characterization of the first-in-class T-cell-engaging bispecific single-chain antibody for targeted immunotherapy of solid tumors expressing the oncofetal protein claudin 6., PMID:27141353
Conditional pulmonary over-expression of Claudin 6 during embryogenesis delays lung morphogenesis., PMID:26198145
Selection of a hepatitis C virus with altered entry factor requirements reveals a genetic interaction between the E1 glycoprotein and claudins., PMID:25820616
Functional analysis of claudin-6 and claudin-9 as entry factors for hepatitis C virus infection of human hepatocytes by using monoclonal antibodies., PMID:23864633
Immunologic and chemical targeting of the tight-junction protein Claudin-6 eliminates tumorigenic human pluripotent stem cells., PMID:23778593
Isolate-dependent use of claudins for cell entry by hepatitis C virus., PMID:23775920
Characterization and evaluation of the antitumour activity of a dual-targeting monoclonal antibody against claudin-3 and claudin-4., PMID:21115905
Distribution and expression pattern of claudins 6, 7, and 9 in diffuse- and intestinal-type gastric adenocarcinomas., PMID:19960275
The role of claudin-based tight junctions in morphogenesis., PMID:19538288
Claudin 6 is a positive marker for atypical teratoid/rhabdoid tumors., PMID:19220299
Changes in the distribution pattern of Claudin tight junction proteins during the progression of mouse skin tumorigenesis., PMID:17945025
Differential expression and subcellular localization of claudin-7, -8, -12, -13, and -15 along the mouse intestine., PMID:16651389
The renal segmental distribution of claudins changes with development., PMID:12110008
Differential expression patterns of claudins, tight junction membrane proteins, in mouse nephron segments., PMID:11912246
Endothelial claudin: claudin-5/TMVCF constitutes tight junction strands in endothelial cells., PMID:10508865
For research use only. Not for human or drug use.
